Ceber M, Salihoglu T (2006). "Ketamine may be the first choice for anesthesia in burn patients". Journal of Burn Care & Research. 27 (5): 760–2. doi:10.1097/01.BCR.0000238091.41737.7C. PMID16998413.
Equinozzi R, Robuschi M (2006). "Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough : a randomized, double-blind, multicenter study". Treatments in Respiratory Medicine. 5 (6): 509–13. doi:10.2165/00151829-200605060-00014. PMID17154678. S2CID58323644.
Lipina T, Labrie V, Weiner I, Roder J (April 2005). "Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia". Psychopharmacology. 179 (1): 54–67. doi:10.1007/s00213-005-2210-x. PMID15759151. S2CID10858756.
Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G (September 2007). "The kynurenic acid hypothesis of schizophrenia". Physiology & Behavior. 92 (1–2): 203–9. doi:10.1016/j.physbeh.2007.05.025. PMID17573079. S2CID46156877.
Aarts MM, Tymianski M (September 2003). "Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors". Biochemical Pharmacology. 66 (6): 877–86. doi:10.1016/S0006-2952(03)00297-1. PMID12963474.
Kristensen JD, Svensson B, Gordh T (November 1992). "The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans". Pain. 51 (2): 249–53. doi:10.1016/0304-3959(92)90266-E. PMID1484720. S2CID37828325.
Rockstroh S, Emre M, Tarral A, Pokorny R (April 1996). "Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans". Psychopharmacology. 124 (3): 261–6. doi:10.1007/BF02246666. PMID8740048. S2CID36727794.
Hargreaves RJ, Hill RG, Iversen LL (1994). "Neuroprotective NMDA Antagonists: The Controversy over Their Potential for Adverse Effects on Cortical Neuronal Morphology". Brain Edema IX. Vol. 60. pp. 15–9. doi:10.1007/978-3-7091-9334-1_4. ISBN978-3-7091-9336-5. PMID7976530. {{cite book}}: |journal= ignored (help)
Sun L, Li Q, Li Q, Zhang Y, Liu D, Jiang H, Pan F, Yew DT (March 2014). "Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys". Addiction Biology. 19 (2): 185–94. doi:10.1111/adb.12004. PMID23145560. S2CID23028521.
Green SM, Coté CJ (August 2009). "Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine". Annals of Emergency Medicine. 54 (2): 181–90. doi:10.1016/j.annemergmed.2008.10.003. PMID18990467.
Morgan CJ, Muetzelfeldt L, Curran HV (January 2010). "Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study". Addiction. 105 (1): 121–33. doi:10.1111/j.1360-0443.2009.02761.x. PMID19919593.
Gardoni F, Di Luca M (September 2006). "New targets for pharmacological intervention in the glutamatergic synapse". European Journal of Pharmacology. 545 (1): 2–10. doi:10.1016/j.ejphar.2006.06.022. PMID16831414.
van den Bos R, Charria Ortiz GA, Cools AR (June 1992). "Injections of the NMDA-antagonist D-2-amino-7-phosphonoheptanoic acid (AP-7) into the nucleus accumbens of rats enhance switching between cue-directed behaviours in a swimming test procedure". Behavioural Brain Research. 48 (2): 165–70. doi:10.1016/S0166-4328(05)80153-6. PMID1535501. S2CID3997779.
Eblen F, Löschmann PA, Wüllner U, Turski L, Klockgether T (March 1996). "Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions". European Journal of Pharmacology. 299 (1–3): 9–16. doi:10.1016/0014-2999(95)00795-4. PMID8901001.
Wong BY, Coulter DA, Choi DW, Prince DA (February 1988). "Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices". Neuroscience Letters. 85 (2): 261–6. doi:10.1016/0304-3940(88)90362-X. PMID2897648. S2CID9903072.
Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW, Farber N, Wozniak DF, Olney JW (October 1993). "Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex". Experimental Neurology. 123 (2): 204–15. doi:10.1006/exnr.1993.1153. PMID8405286. S2CID24839154.
Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA (July 2013). "Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss". Proceedings of the National Academy of Sciences of the United States of America. 110 (27): E2518–27. Bibcode:2013PNAS..110E2518T. doi:10.1073/pnas.1306832110. PMC3704025. PMID23776240.
Grasshoff C, Drexler B, Rudolph U, Antkowiak B (2006). "Anaesthetic drugs: linking molecular actions to clinical effects". Current Pharmaceutical Design. 12 (28): 3665–79. doi:10.2174/138161206778522038. PMID17073666.
Banerjee A, Schepmann D, Köhler J, Würthwein EU, Wünsch B (November 2010). "Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists". Bioorganic & Medicinal Chemistry. 18 (22): 7855–67. doi:10.1016/j.bmc.2010.09.047. PMID20965735.
Nadler V, Mechoulam R, Sokolovsky M (November 1993). "The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain". Neuroscience Letters. 162 (1–2): 43–5. doi:10.1016/0304-3940(93)90555-Y. PMID8121633. S2CID34955663.
Zhang JM, Hu GY (2001). "Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons". Neuroscience. 105 (3): 663–9. doi:10.1016/s0306-4522(01)00206-8. PMID11516831. S2CID25801039.
Karlov D, Barygin O, Dron M, Palyulin V, Grigoriev V, Fedorov M (2019). "Short peptide with an inhibitory activity on the NMDA/Gly-induced currents". SAR and QSAR in Environmental Research. 30 (9): 683–695. doi:10.1080/1062936X.2019.1653965. S2CID202879710.
Muir KW (February 2006). "Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists". Current Opinion in Pharmacology. 6 (1): 53–60. doi:10.1016/j.coph.2005.12.002. PMID16359918.
Hara K, Sata T (January 2007). "Inhibitory effect of gabapentin on N-methyl-D-aspartate receptors expressed in Xenopus oocytes". Acta Anaesthesiologica Scandinavica. 51 (1): 122–8. doi:10.1111/j.1399-6576.2006.01183.x. PMID17073851. S2CID32385475.
Hartley DM, Monyer H, Colamarino SA, Choi DW (1990). "7-Chlorokynurenate Blocks NMDA Receptor-Mediated Neurotoxicity in Murine Cortical Culture". The European Journal of Neuroscience. 2 (4): 291–295. doi:10.1111/j.1460-9568.1990.tb00420.x. PMID12106035. S2CID26088526.
Frankiewicz T, Pilc A, Parsons CG (February 2000). "Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices". Neuropharmacology. 39 (4): 631–42. doi:10.1016/S0028-3908(99)00168-9. PMID10728884. S2CID16639516.
Khan MJ, Seidman MD, Quirk WS, Shivapuja BG (2000). "Effects of kynurenic acid as a glutamate receptor antagonist in the guinea pig". European Archives of Oto-Rhino-Laryngology. 257 (4): 177–81. doi:10.1007/s004050050218. PMID10867830. S2CID21396821.
Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA (July 2013). "Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss". Proceedings of the National Academy of Sciences of the United States of America. 110 (27): E2518–27. Bibcode:2013PNAS..110E2518T. doi:10.1073/pnas.1306832110. PMC3704025. PMID23776240.
Ceber M, Salihoglu T (2006). "Ketamine may be the first choice for anesthesia in burn patients". Journal of Burn Care & Research. 27 (5): 760–2. doi:10.1097/01.BCR.0000238091.41737.7C. PMID16998413.
Heshmati F, Zeinali MB, Noroozinia H, Abbacivash R, Mahoori A (December 2003). "Use of ketamine in severe status asthmaticus in intensive care unit". Iranian Journal of Allergy, Asthma, and Immunology. 2 (4): 175–80. PMID17301376.
Equinozzi R, Robuschi M (2006). "Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough : a randomized, double-blind, multicenter study". Treatments in Respiratory Medicine. 5 (6): 509–13. doi:10.2165/00151829-200605060-00014. PMID17154678. S2CID58323644.
Lipina T, Labrie V, Weiner I, Roder J (April 2005). "Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia". Psychopharmacology. 179 (1): 54–67. doi:10.1007/s00213-005-2210-x. PMID15759151. S2CID10858756.
Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G (September 2007). "The kynurenic acid hypothesis of schizophrenia". Physiology & Behavior. 92 (1–2): 203–9. doi:10.1016/j.physbeh.2007.05.025. PMID17573079. S2CID46156877.
Aarts MM, Tymianski M (September 2003). "Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors". Biochemical Pharmacology. 66 (6): 877–86. doi:10.1016/S0006-2952(03)00297-1. PMID12963474.
Kristensen JD, Svensson B, Gordh T (November 1992). "The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans". Pain. 51 (2): 249–53. doi:10.1016/0304-3959(92)90266-E. PMID1484720. S2CID37828325.
Rockstroh S, Emre M, Tarral A, Pokorny R (April 1996). "Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans". Psychopharmacology. 124 (3): 261–6. doi:10.1007/BF02246666. PMID8740048. S2CID36727794.
Lim DK (January 2003). "Ketamine associated psychedelic effects and dependence". Singapore Medical Journal. 44 (1): 31–4. PMID12762561.
Hargreaves RJ, Hill RG, Iversen LL (1994). "Neuroprotective NMDA Antagonists: The Controversy over Their Potential for Adverse Effects on Cortical Neuronal Morphology". Brain Edema IX. Vol. 60. pp. 15–9. doi:10.1007/978-3-7091-9334-1_4. ISBN978-3-7091-9336-5. PMID7976530. {{cite book}}: |journal= ignored (help)
Sun L, Li Q, Li Q, Zhang Y, Liu D, Jiang H, Pan F, Yew DT (March 2014). "Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys". Addiction Biology. 19 (2): 185–94. doi:10.1111/adb.12004. PMID23145560. S2CID23028521.
Green SM, Coté CJ (August 2009). "Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine". Annals of Emergency Medicine. 54 (2): 181–90. doi:10.1016/j.annemergmed.2008.10.003. PMID18990467.
Morgan CJ, Muetzelfeldt L, Curran HV (January 2010). "Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study". Addiction. 105 (1): 121–33. doi:10.1111/j.1360-0443.2009.02761.x. PMID19919593.
Gardoni F, Di Luca M (September 2006). "New targets for pharmacological intervention in the glutamatergic synapse". European Journal of Pharmacology. 545 (1): 2–10. doi:10.1016/j.ejphar.2006.06.022. PMID16831414.
van den Bos R, Charria Ortiz GA, Cools AR (June 1992). "Injections of the NMDA-antagonist D-2-amino-7-phosphonoheptanoic acid (AP-7) into the nucleus accumbens of rats enhance switching between cue-directed behaviours in a swimming test procedure". Behavioural Brain Research. 48 (2): 165–70. doi:10.1016/S0166-4328(05)80153-6. PMID1535501. S2CID3997779.
Eblen F, Löschmann PA, Wüllner U, Turski L, Klockgether T (March 1996). "Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions". European Journal of Pharmacology. 299 (1–3): 9–16. doi:10.1016/0014-2999(95)00795-4. PMID8901001.
Wong BY, Coulter DA, Choi DW, Prince DA (February 1988). "Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices". Neuroscience Letters. 85 (2): 261–6. doi:10.1016/0304-3940(88)90362-X. PMID2897648. S2CID9903072.
Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW, Farber N, Wozniak DF, Olney JW (October 1993). "Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex". Experimental Neurology. 123 (2): 204–15. doi:10.1006/exnr.1993.1153. PMID8405286. S2CID24839154.
Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA (July 2013). "Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss". Proceedings of the National Academy of Sciences of the United States of America. 110 (27): E2518–27. Bibcode:2013PNAS..110E2518T. doi:10.1073/pnas.1306832110. PMC3704025. PMID23776240.
Grasshoff C, Drexler B, Rudolph U, Antkowiak B (2006). "Anaesthetic drugs: linking molecular actions to clinical effects". Current Pharmaceutical Design. 12 (28): 3665–79. doi:10.2174/138161206778522038. PMID17073666.
Banerjee A, Schepmann D, Köhler J, Würthwein EU, Wünsch B (November 2010). "Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists". Bioorganic & Medicinal Chemistry. 18 (22): 7855–67. doi:10.1016/j.bmc.2010.09.047. PMID20965735.
Nadler V, Mechoulam R, Sokolovsky M (November 1993). "The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain". Neuroscience Letters. 162 (1–2): 43–5. doi:10.1016/0304-3940(93)90555-Y. PMID8121633. S2CID34955663.
Zhang JM, Hu GY (2001). "Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons". Neuroscience. 105 (3): 663–9. doi:10.1016/s0306-4522(01)00206-8. PMID11516831. S2CID25801039.
Muir KW (February 2006). "Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists". Current Opinion in Pharmacology. 6 (1): 53–60. doi:10.1016/j.coph.2005.12.002. PMID16359918.
Hara K, Sata T (January 2007). "Inhibitory effect of gabapentin on N-methyl-D-aspartate receptors expressed in Xenopus oocytes". Acta Anaesthesiologica Scandinavica. 51 (1): 122–8. doi:10.1111/j.1399-6576.2006.01183.x. PMID17073851. S2CID32385475.
Hartley DM, Monyer H, Colamarino SA, Choi DW (1990). "7-Chlorokynurenate Blocks NMDA Receptor-Mediated Neurotoxicity in Murine Cortical Culture". The European Journal of Neuroscience. 2 (4): 291–295. doi:10.1111/j.1460-9568.1990.tb00420.x. PMID12106035. S2CID26088526.
Frankiewicz T, Pilc A, Parsons CG (February 2000). "Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices". Neuropharmacology. 39 (4): 631–42. doi:10.1016/S0028-3908(99)00168-9. PMID10728884. S2CID16639516.
Khan MJ, Seidman MD, Quirk WS, Shivapuja BG (2000). "Effects of kynurenic acid as a glutamate receptor antagonist in the guinea pig". European Archives of Oto-Rhino-Laryngology. 257 (4): 177–81. doi:10.1007/s004050050218. PMID10867830. S2CID21396821.
Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA (July 2013). "Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss". Proceedings of the National Academy of Sciences of the United States of America. 110 (27): E2518–27. Bibcode:2013PNAS..110E2518T. doi:10.1073/pnas.1306832110. PMC3704025. PMID23776240.
"MedlinePlus Drug Information: Amantadine." MedlinePlus website Accessed 29 May 2007
semanticscholar.org
api.semanticscholar.org
Equinozzi R, Robuschi M (2006). "Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough : a randomized, double-blind, multicenter study". Treatments in Respiratory Medicine. 5 (6): 509–13. doi:10.2165/00151829-200605060-00014. PMID17154678. S2CID58323644.
Lipina T, Labrie V, Weiner I, Roder J (April 2005). "Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia". Psychopharmacology. 179 (1): 54–67. doi:10.1007/s00213-005-2210-x. PMID15759151. S2CID10858756.
Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G (September 2007). "The kynurenic acid hypothesis of schizophrenia". Physiology & Behavior. 92 (1–2): 203–9. doi:10.1016/j.physbeh.2007.05.025. PMID17573079. S2CID46156877.
Kristensen JD, Svensson B, Gordh T (November 1992). "The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans". Pain. 51 (2): 249–53. doi:10.1016/0304-3959(92)90266-E. PMID1484720. S2CID37828325.
Rockstroh S, Emre M, Tarral A, Pokorny R (April 1996). "Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans". Psychopharmacology. 124 (3): 261–6. doi:10.1007/BF02246666. PMID8740048. S2CID36727794.
Sun L, Li Q, Li Q, Zhang Y, Liu D, Jiang H, Pan F, Yew DT (March 2014). "Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys". Addiction Biology. 19 (2): 185–94. doi:10.1111/adb.12004. PMID23145560. S2CID23028521.
Farber NB, Heinkel C, Dribben WH, Nemmers B, Jiang X (November 2004). "In the adult CNS, ethanol prevents rather than produces NMDA antagonist-induced neurotoxicity". Brain Research. 1028 (1): 66–74. doi:10.1016/j.brainres.2004.08.065. PMID15518643. S2CID9346522.
Farber NB, Jiang X, Dikranian K, Nemmers B (December 2003). "Muscimol prevents NMDA antagonist neurotoxicity by activating GABAA receptors in several brain regions". Brain Research. 993 (1–2): 90–100. doi:10.1016/j.brainres.2003.09.002. PMID14642834. S2CID39247873.
van den Bos R, Charria Ortiz GA, Cools AR (June 1992). "Injections of the NMDA-antagonist D-2-amino-7-phosphonoheptanoic acid (AP-7) into the nucleus accumbens of rats enhance switching between cue-directed behaviours in a swimming test procedure". Behavioural Brain Research. 48 (2): 165–70. doi:10.1016/S0166-4328(05)80153-6. PMID1535501. S2CID3997779.
Wong BY, Coulter DA, Choi DW, Prince DA (February 1988). "Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices". Neuroscience Letters. 85 (2): 261–6. doi:10.1016/0304-3940(88)90362-X. PMID2897648. S2CID9903072.
Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW, Farber N, Wozniak DF, Olney JW (October 1993). "Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex". Experimental Neurology. 123 (2): 204–15. doi:10.1006/exnr.1993.1153. PMID8405286. S2CID24839154.
Nadler V, Mechoulam R, Sokolovsky M (November 1993). "The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain". Neuroscience Letters. 162 (1–2): 43–5. doi:10.1016/0304-3940(93)90555-Y. PMID8121633. S2CID34955663.
Zhang JM, Hu GY (2001). "Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons". Neuroscience. 105 (3): 663–9. doi:10.1016/s0306-4522(01)00206-8. PMID11516831. S2CID25801039.
Karlov D, Barygin O, Dron M, Palyulin V, Grigoriev V, Fedorov M (2019). "Short peptide with an inhibitory activity on the NMDA/Gly-induced currents". SAR and QSAR in Environmental Research. 30 (9): 683–695. doi:10.1080/1062936X.2019.1653965. S2CID202879710.
Hara K, Sata T (January 2007). "Inhibitory effect of gabapentin on N-methyl-D-aspartate receptors expressed in Xenopus oocytes". Acta Anaesthesiologica Scandinavica. 51 (1): 122–8. doi:10.1111/j.1399-6576.2006.01183.x. PMID17073851. S2CID32385475.
Hartley DM, Monyer H, Colamarino SA, Choi DW (1990). "7-Chlorokynurenate Blocks NMDA Receptor-Mediated Neurotoxicity in Murine Cortical Culture". The European Journal of Neuroscience. 2 (4): 291–295. doi:10.1111/j.1460-9568.1990.tb00420.x. PMID12106035. S2CID26088526.
Frankiewicz T, Pilc A, Parsons CG (February 2000). "Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices". Neuropharmacology. 39 (4): 631–42. doi:10.1016/S0028-3908(99)00168-9. PMID10728884. S2CID16639516.
Khan MJ, Seidman MD, Quirk WS, Shivapuja BG (2000). "Effects of kynurenic acid as a glutamate receptor antagonist in the guinea pig". European Archives of Oto-Rhino-Laryngology. 257 (4): 177–81. doi:10.1007/s004050050218. PMID10867830. S2CID21396821.